Defining the mode of action of cisplatin combined with NUC-1031, a phosphoramidate modification of gemcitabine

The combination of gemcitabine with platinum agents is a widely used chemotherapy regimen for a number of tumour types. Gemcitabine plus cisplatin remains the current therapeutic choice for biliary tract cancer. Gemcitabine is associated with multiple cellular drug resistance mechanisms and other li...

Full description

Bibliographic Details

Published in:	Translational Oncology
Main Authors:	Dillum Patel, Alison L. Dickson, Greice M. Zickuhr, In Hwa Um, Oliver J. Read, Clarissa M. Czekster, Peter Mullen, David J. Harrison, Jennifer Bré
Format:	Article
Language:	English
Published:	Elsevier 2024-12-01
Subjects:	Gemcitabine Cisplatin: NUC-1031 Biliary tract cancer Ovarian cancer DNA damage
Online Access:	http://www.sciencedirect.com/science/article/pii/S1936523324002419